CMBA
AKRO

C.M. Bidwell & Associates’s Akero Therapeutics AKRO Stock Holding History

C.M. Bidwell & Associates’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10
Closed -$534 – 490
2025
Q2 		$534 Hold
10
– – ﹤0.01% 416
2025
Q1 		$405 Buy
+10
New +$424 ﹤0.01% 421
2021
Q2 		– Sell
-6,705
Closed -$195K – 563
2021
Q1 		$195K Buy
6,705
+1,750
+35% +$53K 0.14% 139
2020
Q4 		$128K Buy
+4,955
New +$138K 0.11% 191

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

C.M. Bidwell & Associates's AKRO Position: Q3 2025 in Review

C.M. Bidwell & Associates sold out of Akero Therapeutics (AKRO) in Q3 2025, closing a stake of 10 shares — an estimated $534 sold.

C.M. Bidwell & Associates first reported a position in AKRO in Q4 2020 and held it in 4 quarters. The position peaked at $195K in Q1 2021. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

  • C.M. Bidwell & Associates reported no remaining Akero Therapeutics position as of Q3 2025 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 10 Akero Therapeutics shares in Q3 2025, an estimated $534.
  • C.M. Bidwell & Associates first reported a position in Akero Therapeutics in Q4 2020 and held it in 4 quarters.
  • C.M. Bidwell & Associates's Akero Therapeutics position peaked at $195K in Q1 2021.
  • 265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on C.M. Bidwell & Associates's 13F filing for Q3 2025, filed 13 Nov 2025.